Informes

[E] CARRICK THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF ITS ORAL CDK7 INHIBITOR: CT7001

No hay informes relevantes para este ítem